WhichPepsPeptides. Without the hype.
Laboratory / analytical evidence · SLU-PP-332

In-vitro human liver metabolism study for SLU-PP-332

Human-derived liver metabolism work identified metabolites relevant to detection, but did not administer the compound to people.

Quick read
Laboratory / analytical evidence

What this study tells us

This was laboratory or cell research, not a human treatment trial. It can help explain a mechanism, but it cannot prove clinical benefit or safety in people.

Who was studied?

Human liver S9 fraction

How many?

No participant count — this was laboratory or analytical research.

What happened?

Human-derived liver metabolism work identified metabolites relevant to detection, but did not administer the compound to people.

What stops us overclaiming?

Human-derived tissue is not human clinical exposure.

Need help with terms such as randomized, placebo, endpoint or sample size? Open the glossary →

Key result

Human-derived liver metabolism work identified metabolites relevant to detection, but did not administer the compound to people.

Study details

Study designIn-vitro human-derived metabolism / anti-doping study
PopulationHuman liver S9 fraction
RouteIn vitro
Regimen / exposureSLU-PP-332 incubation with human liver S9
DurationLaboratory metabolism study
ComparatorAnalytical controls
Primary endpoint / questionMetabolite identification
Safety resultNo clinical safety information generated.
Key limitationsHuman-derived tissue is not human clinical exposure.
Registry / identifierPMID 41688415